CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place

Experts explore the growing role of CAR T-cell therapy in the treatment of r/r MM, as well as dive into recent data updates, importance of early referral, and future directions of CAR-T in this rapidly evolving field.

EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

March 31st 2025

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

March 31st 2025

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

EP. 3: Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

April 7th 2025

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

EP. 4: Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

April 7th 2025

Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.

EP. 5: Bridging to CAR T in R/R MM: Best Practices

April 14th 2025

Experts discuss their optimal strategy for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T-cell therapy. They focus on selecting therapies that maintain disease control while awaiting CAR T infusion.

EP. 6: Explaining CAR T: Key Points for Patient Counseling

April 14th 2025

Experts discuss what they share with patients when counseling or introducing chimeric antigen receptor (CAR) T-cell therapy, focusing on the treatment process, potential benefits, risks, and expectations.

EP. 7: Overcoming Barriers to CAR T Referral in R/R MM

April 21st 2025

Experts discuss the challenges and barriers to early referral for chimeric antigen receptor (CAR) T-cell therapy, including logistical, financial, and patient-related factors that may impact timely access to treatment.

EP. 8: Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

April 21st 2025

Experts discuss how they manage chimeric antigen receptor (CAR) T-cell therapy follow-up care, highlighting the coordination between academic and community settings to ensure comprehensive monitoring and support for patients.

EP. 9: Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

April 28th 2025

Experts discuss strategies for managing and mitigating early vs late chimeric antigen receptor (CAR) T-cell therapy–related toxicities, offering advice to practitioners, and share additional clinical pearls on improving the overall CAR T process in academic and community settings.

EP. 10: Exciting Future Horizons for CAR T in MM and Take-Home Messages

April 28th 2025

Experts share their closing thoughts and key take-home messages from the discussion, summarizing important insights and takeaways for enhancing patient care and treatment strategies.